Company profile for Scynexis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. We believe that our lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refr...
We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. We believe that our lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1 Evertrust Plaza 13th Floor Jersey City, NJ 07302
Telephone
Telephone
(201) 884-5485
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Scynexis Transfers Brexafemme NDA to Gsk
Scynexis Transfers Brexafemme NDA to Gsk

19 Nov 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/11/19/3190785/0/en/SCYNEXIS-Completes-Transfer-of-BREXAFEMME-New-Drug-Application-to-GSK.html

GLOBENEWSWIRE
19 Nov 2025

https://www.globenewswire.com/news-release/2025/11/17/3189320/0/en/Scynexis-Announces-Federal-Funding-of-Collaboration-Between-Hackensack-Meridian-CDI-and-Johns-Hopkins-Researchers-to-Develop-New-Therapeutics-Including-Novel-Fungerps-for-Resistant.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3182006/0/en/SCYNEXIS-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
05 Nov 2025

https://www.fiercepharma.com/pharma/gsk-makes-nice-antifungal-partner-scynexis-through-22m-payout-resolve-trial-dispute

FIERCE PHARMA
15 Oct 2025

https://www.globenewswire.com/news-release/2025/09/30/3158537/0/en/SCYNEXIS-Announces-Positive-Results-from-a-Phase-1-Single-Ascending-Dose-and-Multiple-Ascending-Dose-Study-of-its-Second-Generation-Fungerp-SCY-247.html

GLOBENEWSWIRE
30 Sep 2025

https://www.globenewswire.com/news-release/2025/08/25/3138396/0/en/SCYNEXIS-to-Participate-in-the-H-C-Wainwright-27th-Annual-Global-Conference-September-8-10-2025.html

GLOBENEWSWIRE
25 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty